Comparative study on legislative measures for incentivizing supply of orphan drugs and its implications
10.3969/j.issn.1671-332X.2025.01.004
- VernacularTitle:罕见病药品供应激励措施立法比较研究及其启示
- Author:
Xi FENG
1
;
Pei YAN
1
Author Information
1. 南方医科大学 广东 广州 510515
- Publication Type:Journal Article
- Keywords:
Orphan drugs;
Drug accessibility;
Incentive measures;
Comparative study
- From:
Modern Hospital
2025;25(1):8-14
- CountryChina
- Language:Chinese
-
Abstract:
Orphan drugs face the challenge of being unavailable for a long time due to their high investment and low re-turn.In response,the United States,European Union,and some countries and regions in Asia have implemented various incen-tive measures(including financial and non-financial incentives)for the supply of orphan drugs,achieving significant results.China has also introduced corresponding measures for the supply of orphan drugs,but compared to countries and regions such as Europe and the United States,the incentives are insufficient.China should further learn from international experiences,define criteria for identifying orphan drugs,adopt"dual-track"incentive measures to promote the supply of orphan drugs,and also take preventive measures in price regulation and risk control to mitigate any negative effects associated with the supply of orphan drugs.
